Q-Med: Invitation to Press and Analyst Briefing on the Year-End Report.STOCKHOLM, Sweden -- Q-Med (STO:QMED): Friday, February 10, 10:30 a.m, (CET CET abbr. Central European Time CET Central European Time CET n abbr (= Central European Time) → hora de Europa central CET abbr ) at Operaterrassen, Stockholm Bengt Agerup, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Erika Kjellberg Eriksson, CFO See Chief Financial Officer. , will present the company and comment on the report. Moderator: Kristofer Liljeberg Svensson, Carnegie To participate, please register in one of the following ways: at www.financialhearings.com or by phone + 46(0) 8 411 43 80. Friday's presentation can also be followed live by telephone conference, which is accessible by dialling + 46 (0) 8 598 062 47. The slide presentation will be available at: www.q-med.com, on Friday, February 10 at 10.00 a.m. Q-Med's year-end report will be published around 08:00 a.m Friday, February 10. Financial information from Q-Med during Year 2006: 3 May Interim Report January - March 2006 3 May Annual General Meeting 24 July Interim Report January - June 2006 23 October Interim Report January - September 2006 Note: Q-Med AB operates under the name of Q-Med Scandinavia, Inc. in the USA. Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces, markets and sells medical implants. All products are based on the company's patented NASHA NASHA Non-Animal, Stabilized Hyaluronic Acid (trademark of Q-Med AB; Uppsala, Sweden) NASHA National Association for Speech and Hearing Action (Rockville, MD) technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation malformation /mal·for·ma·tion/ (-for-ma´shun) 1. a type of anomaly. 2. a morphologic defect of an organ or larger region of the body, resulting from an intrinsically abnormal developmental process. of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence stress urinary incontinence n. See stress incontinence. in women has been sold in Europe since July 2002. Q-Med today has 540 employees, with approximately 350 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the O- list of the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. . This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion